In a ‘Real-World’, Clinic-Based Community Setting, Sorafenib Dose of 400 mg/day is as Effective as Standard Dose of 800 mg/day in Patients with Advanced Hepatocellular Carcimona, with Better Tolerance and Similar Survival | Zendy

Alexandra Shingina | Zendy; Al Moutaz Hashim | Zendy; Mazhar Haque | Zendy; Michael W.H. Suen | Zendy; Eric M. Yoshida | Zendy; Sharlene Gill | Zendy; Fergal Donnellan | Zendy; Alan Weiss | Zendy

Open Access

In a ‘Real-World’, Clinic-Based Community Setting, Sorafenib Dose of 400 mg/day is as Effective as Standard Dose of 800 mg/day in Patients with Advanced Hepatocellular Carcimona, with Better Tolerance and Similar Survival

Author(s) -

Alexandra Shingina,

Al Moutaz Hashim,

Mazhar Haque,

Michael W.H. Suen,

Eric M. Yoshida,

Sharlene Gill,

Fergal Donnellan,

Alan Weiss

Publication year - 2013

Publication title -

canadian journal of gastroenterology

Language(s) - English

Resource type - Journals

eISSN - 1916-7237

pISSN - 0835-7900

DOI - 10.1155/2013/170546

Subject(s) - sorafenib , medicine , hepatocellular carcinoma , adverse effect , incidence (geometry) , retrospective cohort study , liver cancer , cancer , gastroenterology , physics , optics

Sorafenib, an oral multityrosine kinase inhibitor, has been approved for treatment of unresectable hepatocellular carcinoma (HCC). British Columbia (BC) was the first province in Canada to provide drug coverage for sorafenib.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research